To the editor:
A 74-year-old woman with hepatitis C and hepatocellular carcinoma underwent deceased donor liver transplant (LT) from a male donor in August 2008. Donor and recipient were blood group A+ and 2-loci HLA matched (DR01 and DR15). Initial immunosuppression included a corticosteroid taper and tacrolimus. On postoperative day (POD) 28, she developed a papular erythematous rash, diarrhea, and neutropenia. Skin biopsy showed perivascular lymphocytic infiltrate with necrotic keratinocytes and full thickness epidermal necrosis. FISH analysis demonstrated XY-chimerism in both peripheral blood (29.2%) and skin (18.5%, 37/200 nuclei) consistent with graft-versus-host disease (GVHD). Bone marrow biopsy showed < 10% cellularity with XY chimerism (2/10 nuclei) on karyotype analysis. Liver function tests were normal. High dose steroids and mycophenolate mofetil 500mg TID were added. The patient developed refractory neutropenia and thrombocytopenia. After failing a trial of IVIG (0.5mg/kg/d) and rabbit anti-thymocyte globulin (rATG; 1.5mg/kg/d), we sought a donor for rescue hematopoietic stem cell transplantation (HSCT) based on prior success with this strategy in GVHD following HSCT.1
On POD 42 she received a haploidentical CD34+ selected (Baxter Isolex 300i) HSCT (2.01 × 106 cells, CD3+ 0.3%) from her son (3-loci HLA match) after 7 days of rATG. A second infusion of 0.96 × 106 (CD3+ 0.4%) cells was given on POD 45. HSCT was not on study protocol. Informed consent was obtained from both patient and donor. Immunosuppression regimen at HSCT included tacrolimus, mycophenolate mofetil 500mg TID, and prednisone (30mg BID). Neutropenia and thrombocytopenia resolved 10 (POD 53) and 46 (POD 88) days after HSCT, respectively (Figure 1). Chimerism studies demonstrated transient XY chimerism of peripheral blood (13%) on POD 58 and near complete reconstitution of bone marrow with XX cells on POD 113 (98.85%; Figure 1). Thirty-two months after LT, she has stable liver graft function and normal hematopoietic cell lines.
Acute GVHD is a rare complication following LT with an estimated incidence of < 1% and a high mortality rate (80%).2,3 This is the first report of lymphodepletion followed by haploidentical HSCT for the management of GVHD following LT. After failure of traditional therapies involving augmentation of immunosuppression,4-6 we sought a novel intervention based on prior data demonstrating resolution of refractory GVHD following HSCT in 50% of patients after secondary allogeneic HSCT.1
The mechanism of action is unclear. Graft-versus-tumor effect has been demonstrated with higher doses of CD3+ infusions (≥ 1 × 108 cells). Our mean CD3+ yield post-CD34+ selection of 0.35% (1 × 105 cells) measured by flow cytometry is below this reported threshold, making a direct cytotoxic graft-versus-graft effect possible but less likely.7 Transient engraftment has been reported as early as 10 days post-HSCT with subsequent restoration of recipient chimerism by as early as day 28.7 It is unclear if this occurred since STR analysis was not performed. CD34+ progenitor cell modulation of antigen presentation may have contributed to resolution of GVHD, similar to mechanisms proposed in mesenchymal stem cell infusions.8,9 We conclude that rescue HSCT should be considered for GVHD following LT, as most cases are refractory to current approaches.
Acknowledgments: All peripheral blood and skin chimerism studies were performed at the Cytogenetics Laboratory at Mayo Clinic (Rochester, MN). Bone marrow karyotype analysis was performed at Children's Memorial Hospital (Chicago, IL) by Dr Katrin Carlson Leuer.
Correspondence: Dr Josh Levitsky, Department of Medicine, Division of Hepatology, Northwestern University Feinberg School of Medicine, 676 N St Clair St, Arkes 19th Fl, Chicago, IL 60611; e-mail: firstname.lastname@example.org.